Mounjaro and Wegovy are two of the biggest names in the world of weight-loss drugs but it's been unclear which is more ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks.

Oral semaglutide demonstrated superior cardiometabolic outcomes relative to placebo and active comparators, including empaglifozin, in T2D.

GLP-1 RA helped resolution of steatohepatitis without worsening fibrosis and reduced liver fibrosis without worsening steatohepatitis.

Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.

If you're considering taking a GLP-1 medication, and you also have a digestive condition, you may be wondering about side ...

The first head-to-head trial of obesity drugs reveals a clear winner for effective weight loss. But how does it work, and what are the long-term effects? Anna Magee reports ...

Pregnant women with metabolic dysfunction-associated steatotic liver disease (MASLD) have an increased risk of giving birth prematurely and the risk increase cannot be explained by obesity, according ...

Scientists are continuing to find evidence that GLP-1 medications can temper cravings for alcohol and other drugs.

Popular obesity and diabetes drugs called GLP-1 medications may have added benefits, with a new study finding they helped heavy drinkers cut alcohol consumption by nearly 70%.